Phase 2 N=30 Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age
Pain, Postoperative
Primary: Plasma Concentration of Diclofenac — 29647.9; 35131.0 mL/hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
Pulmonary Disease, Chronic Obstructive
Primary: Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event — 2; 9; 0; 1 Participants
Phase 2 N=107 Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 4.83; 7.23 months
Phase 2 N=28 Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
Chronic Idiopathic Urticaria
Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores
Phase 2 N=56 Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.9 months
Phase 2 N=14 Omalizumab in the Treatment of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Phase 2 N=20 Effect of Quetiapine on Marijuana Withdrawal and Relapse
Marijuana Smoking
Primary: Measure of Relapse: Change in Puffs Chosen Between Baseline and Relapse Phase — 2.5; 1.5 Puffs
Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Phase 2 N=111 Sym004 in Patients With Advanced Solid Tumors
Metastatic Colorectal Cancer
Primary: Number of Participants With Adverse Events (AEs) — 20; 29; 13; 12 Participants
Phase 2 N=170 Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
Type 1 Diabetes
Primary: Event-Specific Survival Comparisons — 22; 8; 9; 1 Participants — p=0.01
Phase 2 N=100 Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
Arthralgia · Musculoskeletal Complications · Pain
Primary: Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness — 12; 1…
Phase 2 N=100 Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Abnormal Biochemical Laboratory Values. — 0; 0; 48; 50 Participants
Phase 2 N=171 Clinical Trial of Topiramate for Cocaine Addiction
Cocaine Dependence
Primary: Proportion of Cocaine Positive Urine Samples Per Treatment Condition — 45.4; 42.7; 53.5; 46.5 percentage of positive urine samples — p=0.531
Phase 2 N=7 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia
Oromandibular Dystonia · Cranial Dystonia
Primary: Percent Change of the Sum of the Eyes, Mouth, Speech and Swallowing Subscores of the Burke-Fahn-Marsden (BFM) Dystonia Scale. — 12.16; 31.25 percent change
Phase 2 N=39 Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
Cancer
Primary: Objective Response Rate (ORR) — 86 percentage of participants